Navigation Links
ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the American Podiatric Medical Association (APMA) Annual Scientific Meeting in Toronto, Canada
Date:7/29/2009

ADDISON, Texas, July 29, /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced today that the application of Altrazeal(TM) and best clinical practice will be demonstrated in a hands-on Wound Care Pre Conference Workshop at the APMA Annual Scientific Meeting July 28 - August 2. In addition, clinical evidence on the treatment of wounds using Altrazeal(TM) Transforming Powder Dressing will be presented on posters during the meeting.

Renaat Van den Hooff, President and CEO of ULURU Inc., commented, "These presentations are a reflection of our ongoing commitment to publish clinical evidence relating to Altrazeal(TM) across all wound types and are an integral part of our 2009 business strategy."

Dr. Brock Liden, DPM and Faculty at the APMA Annual Meeting of Berger Health Care Center, Circleville, Iowa, will be presenting a lecture on how to apply and incorporate Altrazeal(TM) in clinical practice. Following the lecture, workshop participants will be able to learn application techniques and receive clinical guidance for treating wounds with Altrazeal(TM) in a rotation using porcine tissue as simulated wounds.

Commenting on the workshop, Dr. John St. John, Vice President R&D of ULURU Inc., stated, "Altrazeal(TM) has provided clinical benefits in the treatment of chronic wounds. We are excited that this workshop will provide clinicians with the opportunity to learn best clinical practice with Altrazeal(TM) and are confident that this will help in wound treatment at their clinics."

Several clinicians will also be presenting poster presentations on various applications of Altrazeal(TM) in woundcare at the APMA Conference. Tracey Vlahovic, DPM of Temple University is co-author of a poster detailing applications of Altrazeal(TM) in difficult to treat wounds. Greg Bohn, MD of Bettendorf, Iowa, will present a poster that details pain reduction experienced by patients treated with Altrazeal(TM). A poster will be presented by the team of David Armstrong, DPM, Ryan Fitzgerald, DPM, and Manish Bharara from the University of Arizona on the use of Altrazeal(TM) in the management of wounds associated with limb salvage.

Details of the APMA Annual Scientific Meeting are available online athttp://www.apma.org/Members/Events/TheNational.aspx

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal(TM), please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, biocompatibility, ease of application, success in wound healing, clinical outcomes, and suitability of Altrazeal(TM), and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
9. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
10. ULURU Inc. Reports First Quarter 2008 Financial Results
11. ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Aimed at ... human interest stories, which come courtesy of leaders in the nursing and health care ... from leading advocates and associations—namely Abilene Christian University. , As the nursing industry ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a ... (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the 90 ... their favorite way to cook a hot dog, far outpacing other cooking methods such ...
(Date:5/26/2016)... Atlanta, Georgia (PRWEB) , ... May 26, 2016 ... ... a certificate in intellectual property (IP) to its specialty academic programs. , Answering ... joins the college’s existing certificate programs in health law, and environmental and land ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology: